Rituximab is a chimeric mouse/human monoclonal antibody (mAb) therapy with binding
specificity to CD20. It was the first therapeutic antibody approved for oncology patients and …

Immune dysregulation is a cardinal feature of chronic lymphocytic leukemia (CLL) from its
early stage and worsens during clinical observation, even in absence of disease …

Representing the major cause of morbidity and mortality for chronic lymphocytic leukemia
(CLL) patients, immunosuppression is a common feature of the disease. Effectors of the …

Constituent of innate immunity, complement is present in the tumor microenvironment. The
functions of complement include clearance of pathogens and maintenance of homeostasis …

Unconjugated anti-cancer IgG1 monoclonal antibodies (mAbs) activate antibody-dependent
cellular cytotoxicity (ADCC) by natural killer (NK) cells and antibody-dependent cellular …

Complement is recognized as a key player in a wide range of normal as well as disease-
related immune, developmental and homeostatic processes. Knowledge of complement …

Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by a wide range of
tumor-induced alterations, which affect both the innate and adaptive arms of the immune …

Constituting a part of the innate immune system, the complement system consists of over 50
proteins either acting as part of a 3-branch activation cascade, a well-differentiated …

Inflammation is a key component of the tumor microenvironment. Tumor-associated
macrophages (TAMs) and tumor-associated neutrophils (TANs) are prototypic inflammatory …

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the world.
Patient with CLL are at particular risk for infections due to inherent disease-related immune …